A commentary in the Journal of Cancer Research and Clinical Oncology challenged how clinicians interpret exceptional individual responses in multiple myeloma case narratives involving melflufen. The authors warned that striking single-patient outcomes can obscure subgroup-specific safety or efficacy limitations and may distort how the evidence base is summarized. For the field, the piece is a reminder that case-level “signals” need careful statistical framing before they are generalized. It also underscores the need for clearer rules in how sponsors and clinicians communicate rare but impactful response observations in oncology.